Elemene Liposomes in Endometrial Cancer

The goal of this clinical trial is to learn if Elemene Liposomes, combined with carboplatin and paclitaxel (TC) chemotherapy can improve prognosis in patients with advanced or recurrent endometrial cancer. The main question it aims to answer is: Does adding Elemene Liposomes to TC chemotherapy can delay disease recurrence time in patients with advanced or recurrent endometrial carcinoma. Researchers will compare Elemene Liposomes +TC chemotherapy to TC chemotherapy alone to see if Elemene Liposomes, combined with carboplatin and paclitaxel (TC) chemotherapy can improve prognosis in patients with advanced or recurrent endometrial cancer. Participants will: * Receive TC Chemotherapy every 21 days, for a total of 6 cycles. * Take intravenous infusion of Elemene liposome injection every day from day 1 to day 7 of cycle 1 and 2, and take oral Elemene emulsion twice every day, from day 1 to day 14 of cycles 3 to cycle 6. (no intravenous or oral Elemene will be given in comparison group) * Visit the clinic for checkups and tests once every 21 days during treatment and every 3 to 12 months after the treatment is completed.

NCT Number	NCT07738315
Lead Sponsor	Women's Hospital School Of Medicine Zhejiang University Collaborators: Beijing Friendship Hospital, The First Affiliated Hospital of Zhengzhou University, Second Affiliated Hospital of Wenzhou Medical University, Second Affiliated Hospital, Zhejiang University, School of Medicine, Jiaxing Maternity and Child Health Care Hospital, Jiangxi Maternal and Child Health Hospital, Fujian Maternity and Child Health Hospital, Ningbo Women & Children's Hospital
Conditions	Endometrial Carcinoma
Enrollment	212 participants
Start Date	2026-08-01
Primary Completion	2031-08 (estimated)
Study Completion	2031-09 (estimated)
Updated on ClinicalTrials.gov	2026-07-31